XPO1 and Miyoshi myopathy: Further clinical studies that include optimizing dosing schedules to prime the T-cell repertoire or post-T-cell therapy to aid the persistence of CAR-T activity are needed to evaluate the impact of XPO1 inhibitors on CAR-T and MM cell immune susceptibility.